DCM
TPST icon

Driehaus Capital Management’s Tempest Therapeutics TPST Stock Holding History

Driehaus Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-16
Closed -$2.11M – 548
2014
Q4 		$2.11M Buy
+16
New +$1.17M 0.09% 298

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Driehaus Capital Management's TPST Position: Q1 2015 in Review

Driehaus Capital Management sold out of Tempest Therapeutics (TPST) in Q1 2015, closing a stake of 16 shares — an estimated $2.11M sold.

Driehaus Capital Management first reported a position in TPST in Q4 2014 and held it in 1 quarter. The position peaked at $2.11M in Q4 2014. 86 funds tracked by Wall St. Rank hold TPST as of Q1 2015.

  • Driehaus Capital Management reported no remaining Tempest Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Driehaus Capital Management sold 16 Tempest Therapeutics shares in Q1 2015, an estimated $2.11M.
  • Driehaus Capital Management first reported a position in Tempest Therapeutics in Q4 2014 and held it in 1 quarter.
  • Driehaus Capital Management's Tempest Therapeutics position peaked at $2.11M in Q4 2014.
  • 86 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2015.

Based on Driehaus Capital Management's 13F filing for Q1 2015, filed 15 May 2015.